Our findings were in line with previous studies that repressing TNKS activity through either genetic or pharmacological approaches antagonized canonical Wnt/β-catenin signaling and inhibited the progression of lung cancer [27], hepatocellular cancer [13], colon cancer [28], gastric cancer [14], and breast cancer [10], indicating that TNKS act as an oncogene may be a common event in the development of cancers. This evidence concerns the gene TNKS and breast carcinoma.